NCT05713734 Bleeding of Unknown Cause: a Swiss Case-control Study
| NCT ID | NCT05713734 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Geneva |
| Condition | Bleeding Disorder |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2023-04-01 |
| Primary Completion | 2026-06-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2023-04-01 with a primary completion date of 2026-06-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective cohort is to identified specific biological patterns in patients with a bleeding of unknown cause and to study the specific mechanisms of the bleeding disorder for each subset of patients.
Eligibility Criteria
Inclusion Criteria: * Man with ISTH BAT\>3. If the calculated score includes a surgical bleeding, then two other items of the score should be \>0 * Woman with ISTH BAT \>5 points. If the calculated score includes a surgical or a postpartum bleeding, then two other items of the score should be \>0 Exclusion Criteria: * Ongoing pregnancy * Intake of antithrombotic treatment or non-steroidal anti-inflammatory drugs for least 10 days at time of blood collection * Intake of antifibrinolytic or blood product administration (factor concentrate, frozen fresh plasma, prothrombin complex concentrate) for least 14 days before blood collection * Active cancer (defined as cancer diagnosis within the last five years or treatment within the two last years before study inclusion) * Active autoimmune disease * Active chronic inflammatory disease * Severe liver disease (cirrhosis \> Child A) * Renal insufficiency stage 3 * Active or recent infection (within the last 30 days) * Recent hospitalization (\<3 months) * Recent surgery (\<3 months) * Recent trauma requiring medical intervention (\<3 months)
Contact & Investigator
Alessandro Casini
PRINCIPAL INVESTIGATOR
University Hospitals of Geneva
Frequently Asked Questions
Who can join the NCT05713734 clinical trial?
This trial is open to participants of all sexes, aged 16 Years or older, up to 65 Years, studying Bleeding Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05713734 currently recruiting?
Yes, NCT05713734 is actively recruiting participants. Contact the research team at alessandro.casini@hcuge.ch for enrollment information.
Where is the NCT05713734 trial being conducted?
This trial is being conducted at Bellinzona, Switzerland, Bern, Switzerland, Geneva, Switzerland, Lausanne, Switzerland and 3 additional locations.
Who is sponsoring the NCT05713734 clinical trial?
NCT05713734 is sponsored by University Hospital, Geneva. The principal investigator is Alessandro Casini at University Hospitals of Geneva. The trial plans to enroll 400 participants.